Real Estate, Ready?

The real estate index IYR has been struggleing at resistance for months.  Yesterday’s action was a swift break lower to the bottom of the range.

Inverse fund DRV (3X inverse IYR) had is largest single day gain since mid-May of last year.

The weekly chart shows the four-month struggle at resistance as well as MACD bearish divergence.

IYR may attempt to test slightly higher (DRV down) during this session.

If so, we’ll be looking to position short via DRV; not advice not a recommendation.

Moving on to biotech.  Yesterday’s action was a good example of negative bias in LABD.  Even though IBB closed lower, LABD closed lower as well.

The LABD position was closed out as shown (above) and the BIS positions maintained.

Note the R-Exit value.

This represents the gain on the amount risked. If $1,000 was risked on the trade, it returned $8,540.

Update will be forthcoming if/when a DRV position is established.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Dow, S&P, Outside Down

So, this is it?

As this juncture (11:06 a.m. EST), both the Dow and S&P have key reversals; and now the QQQs, and Russell 2000, have just joined them.

If they hold and decline from here, reversing from all time highs, we can add that data to our empirical “Holiday Turns

Holiday turns … markets tend to reverse just before, during, or just after a holiday week.

In the biotech arena, this morning’s gap higher (IBB) closed the distance from price action to the stop for inverse funds BIS and LABD.

That closure opportunity was used to increase the short position (via BIS) in one of the managed accounts.  Not advice, not a recommendation.

The IBB bearish divergence is beginning to take shape.

Positions:

Note: “Close” prices as of 11:03 a.m. EST

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Corn Goes Vertical

Ever since the inland hurricane, the ‘Derecho’ of August 10th, it’s never been the same for corn. Now, it’s going vertical.

The entire U.S. agricultural food supply infrastructure is being systematically dismantled.  Control the food, control the population. Simple.

It seems the ‘preppers’ tend to focus on stockpiling silver and gold.

If your’re getting ready for what’s coming, from a historical perspective, that’s not the place to start.

Going way back …. thousands of years, during the famine in Egypt of Joseph’s time, we have this:

“And Joseph gathered corn as the sand of the sea, very much, until he left numbering; for it was without number”

“And the famine was over all the face of the Earth: and Joseph opened all the storehouses and sold unto the Egyptians: and the famine waxed sore in the land of Egypt.”

“And all countries came unto Joseph for to buy corn; because that the famine was so sore in all lands.”

Gen 41:  Vs.  49, 56, 57, KJV

They paid for the corn first, with gold and silver.  Then they paid with their livestock.  Then they paid by selling themselves into life-long slavery. We can equate that last part (slavery) as getting the vax.

As corn is going vertical, the bond market is signaling its move as well.

Just now, today, TLT is rotating higher.

Yesterday, Steven Van Metre showed a chart (time stamp 10:00) of the speculators beginning to back off their historic short position.

They’ve figured out they’re trapped. Now, they’re trying to sneak out the door without being completely impaled on a sharp bond spike.

The S&P, Dow, NASDAQ, Russell 2000, all appear to be holding near their highs.

Biotech (IBB), as reported yesterday, is different.

Something major is brewing below the surface with the biotech deception.  Price action itself is showing it’s the place to be for the short-side.

Further info on biotech’s downside is here and here.

Positions remain unchanged (as of 3:02 p.m. EST).  Stops have been moved; not advice, not a recommendation.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Class Action

Markets press on, new highs. However, biotech (IBB) is losing luster.

It could be just a temporary blip on the road upward.

Or, there could be something else afoot not known to the general public … and possibly not even known to professional speculators and market traders.

The video link below is to an alternate (independent) platform. One among many popping up in response to ‘adjustments’ being made by YouTube.

The video at this link is nearly an hour long.  It’s one of those things that upon viewing the entire presentation, one can never be the same.

 Viewer beware.  For those with short attentions, fast forward to Time Stamp 22:50, for the meat.

Wyckoff stated a century ago ‘the reason for a move is always revealed after the fact’; we might find if IBB reverses from here and does not look back, the link above may ultimately become the ‘reason’ for such a move.

Imagine if this presentation becomes widespread knowledge … where will biotech be then?

Of course, price action is always the final arbiter.  Positions (and stops) remain unchanged.

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Crowded Trades

Gold miner (GDX) bulls and bears have been fighting in a crowded trade since late November.

This morning’s GDX retrace up (and now down) from yesterday is a case in point. 

In such a choppy environment, inverse funds lose market value (downside bias) quickly and trades need to be avoided.

Meanwhile, on the other side of the market, biotech (IBB) has formed a top, reversed, and posted a new weekly low today.

An hourly trend-line has been formed as well (not shown). 

If it holds as (or if) IBB declines past current support (~152 area), that hourly trend is moving lower at just over -96%, annualized.

Maintaining negative trend, with declining momentum on both daily and weekly timeframes is what we’re looking for.

The objective (not advice, not a recommendation) is to move stops (shown below) and maintain the trade until stopped out or trend break.

As of this post (1:03 p.m. EST), the current price of LABD and BIS are listed in the ‘Close’ column. 

The “R-G/L” is from Dr. Van Tharp’s concept of Risk Gain/Loss.

Example:  If $1,000 of capital was “risked” (entry-to-stop) on the LABD, position, that position is now up by 6.83-R, or $6,830.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Massive Market Distortions

It’s hard to describe how stretched the market really is; how ‘the euphoria is so maximized’, as quoted by David Quintieri of the Money GPS.

His latest report, delves into published articles that contain one market stretched quote after another. 

Perhaps, the most frightening is: ”This does not feel like the top”.

You can find that report at this link.  The quotes listed above and more, start around the 1:40, time stamp.

In the markets as of this post (2:08 p.m. EST), biotech (IBB) continues to erode throughout the session. 

The firm has made one LABD (3X, Inverse) and two BIS (2X, Inverse) entries this session so far. Not advice, not a recommendation.

Note the stop progression on BIS entries.

Positions are below; not advice, not a recommendation:

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Chart Nuances

It’s been a while since biotech (IBB) was on the radar.

We’re going to look at the thirty-minute chart of 2X Inverse fund BIS, to show the change in character.

The first two oval areas after each up move in BIS (IBB down), was fully retraced. Not only that, the retrace occurred on the same day.

Not so with the last oval, today.

BIS has a changed character.  The thirty-minute bar was not retraced; telling us we’re at the danger point where the risk is least.

Both the weekly and daily MACD indicators show momentum has shifted; stalled (on weekly) and has turned lower on the daily.

As far as shorting the biotech sector, any takers?  It’s not like the other crowded trades; Dow, NASDAQ, S&P, and on.

As this post is being written BIS is edging back slightly to the entry point @ BIS, 22.23.

In so doing, there may be an hourly trend line forming.  If that happens, updates will be forthcoming.

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Trade Actions, Early Session

A brief list of changes:

Exit as planned on DUST. Stop was hit

Trader’s discretionary exit on DUG:  Gain ~ 4.80%

Entered short IBB via LABD (3X inverse) and BIS (2X inverse). Not advice, not a recommendation.

The biotech sector has lost momentum. 

Weekly MACD has diverged and is now flat. Additional analysis to come.

Position table is shown below:

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Massive Volume: DUG

Inverse Oil ETF, DUG volume went off the scale today; the highest in at least four years.

The short-squeeze top in the sector, using XOP as the proxy was identified before today’s open in this report.

At that time, there was nothing significant about either XOP, or the inverse DUG other than being at opposite price extremes.

Today’s action changed that view. 

Apparently the juncture was significant enough; Today’s transaction volume in DUG, amounted to approximately $23-million.

That’s a huge number. Typical action is around $4-million.

Oil is inversely related to the dollar at this point.  The dollar proxy, UUP reached a new trend low last week but seems to have found support the past three sessions.

Being short the oil and gas sector via DUG (not advice, not a recommendation) is essentially a leveraged bet on a dollar rally.

In other markets, after weeks of analysis and planning, biotech had its reversal but we’re not in it (on the short side) having exited yesterday.

Not to worry; the massive volume inflow to DUG suggests that we’re on the right track with who (or what) is going to be most vulnerable to a market reversal.

Biotech (IBB) price action may retrace upwards to test. If and when it does, we’ll re-evaluate.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.